Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients

Journal of Neuroimmunology

Volumn 105, Issue 1, 2000, Pages 91-95

  Perini, P ^a   Wadhwa, M ^b   Buttarello, M ^c   Meager, A ^b   Facchinetti, A ^c   Thorpe, R ^b   Biasi, G ^d   Gallo, P ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anti interferon beta antibodies; Interferon beta; Multiple sclerosis; Natural killer cells

Indexed keywords

BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; ANTIBODY; BETA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; BLOOD; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTIBODIES; FEMALE; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0034194927     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00196-X     Document Type: Article

References (20)

1. Däubener W., Waganat N., Piltz K., et al. A new, simple, bioassay for human IFNγ J Immunol Methods. 168:1994;39-43.
2. Fierlbeck G., Ulmer A., Schreiner T., et al. Pharmacodynamics of recombinant IFNβ during long-term treatment of malignant melanoma. J Interf Cytok Res. 16:1996;777-781.
3. Hauser S.L., Ault K.A., Levin M.J., et al. J Immunol. 127:1981;1114-1117.
4. Horwitz D.A., Gray J.D., Ohtsuda K., Hirokawa M., Takahashi T. The immunoregulatory effects of NK cells: the role of TGFβ and implications for autoimmunity. Immunol Today. 17:1997;174-176.
5. Hunter C.A., Gabriel K.E., Radzanowski T., et al. Type I interferons enhance production of IFNγ by NK cells. Immunol Lett. 59:1997;1-5.
6. Kastrukoff L.F., Morgan N.G., Aziz T.M., et al. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J Neuroimmunol. 37:1988;236-244.
7. Kastrukoff L.F., Morgan N.G., Zecchini D., et al. Natural killer cells in relapsing multiple sclerosis. Effect of treatment with interferon β-1b. Neurology. 52:1999;351-359.
8. Kawade Y. Quantification of neutralization of interferon by antibody. Methods Enzymol. 119:1986;558-573.
9. Kos F.J., Engleman E.G. Immune regulation: a critical link between NK cells and CTLs. Immunol Today. 17:1996;174-176.
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
11. Jewell A.P., Worman C.P., Giles F.J., Goldstone A.H. Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukemia receiving interferon-alpha therapy. Leukemia Lymphoma. 24:1997;327-333.
12. Larocca A.P., Leung S.C., Marcus S.G., et al. Evaluation of neutralising antibodies in patients treated with recombinant interferon-βser. J Interfer Res Suppl. 1:1989;S51-60.
13. Munschauer F.E., Hartrich L.A., Stewart C.C., Jacobs L. Circulating natural killer but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol. 62:1995;177-181.
14. Neighbour P.A., Bloom B.R. The interferon-natural killer cell system in multiple sclerosis. Clin Immunol Allergy. 2:1982;279-295.
15. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
16. Rajan G.P., Seifert B., Prummer O., et al. Incidence and in vivo relevance of anti- interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitrein or PUVA. Arch Dermatol Res. 288:1996;543-548.
17. Reiter Z. Interferon. A major regulator of natural killer cell-mediated cytotoxicity. J Interfer Res. 13:1993;247-257.
18. Rice G.P.A., Casali P., Mertigan T.C., et al. Natural killer cell activity in patients with multiple sclerosis given interferon. Ann Neurol. 14:1983;333-338.
19. Öberg K., Alm G., Magnusson A., et al. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: Development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 81:1989;531-535.
20. Wadhwa M., Meager A., Dilger P. et al. (1999) Neutralizing antibodies to granulocyte macrophage colony stimulating factor, interleukin-1α and interferon α, but not other cytokines in human immunoglobulin preparations. Immunology, in press.